Jafron Biomedical (300529.SZ) issued a forecasted increase, with an estimated annual net profit of 800 million to 860 million yuan, a year-on-year growth of 83% to 97%.
Jianfan biotechnology (300529.SZ) disclosed the announcement of the increase in performance for the year 2024. The company expects that the net profit belonging to the listed company...
Jafron Biomedical (300529.SZ) disclosed its performance forecast for 2024, with the company expecting a net profit attributable to shareholders of the listed company of 8 billion to 8.6 billion yuan, a year-on-year increase of 83% to 97%; the net profit after deducting non-recurring gains and losses is expected to be 7.45 billion to 8.05 billion yuan, a year-on-year increase of 82% to 97%.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
